Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | F9 | P00740 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9863137 | 0.89 | PPARA (0.67) | PPARAPPARGHSD17B10GAAKDM4E | |
| SCHEMBL11828515 | 0.85 | PPARA (0.63) | PPARAPPARGHSD17B10GAAKDM4E | |
| SCHEMBL4842029 | 0.85 | KDM4E (0.55) | GAAKDM4ENPSR1ALDH1A1LMNA | |
| SCHEMBL2909364 | 0.84 | HSD17B10 (0.59) | HSD17B10GAAKDM4EALDH1A1LMNA | |
| SCHEMBL6494581 | 0.84 | GAA (0.66) | PPARAPPARGHSD17B10GAAKDM4E | |
| SCHEMBL24092749 | 0.84 | HSD17B10 (0.56) | PPARAPPARGHSD17B10KDM4EALDH1A1 | |
| SCHEMBL987722 | 0.84 | CYSLTR2 (0.56) | GAAKDM4ENPSR1ALDH1A1LMNA | |
| SCHEMBL30350771 | 0.83 | GAA (0.55) | PPARAPPARGHSD17B10GAAKDM4E | |
| SCHEMBL12611682 | 0.83 | GAA (0.55) | PPARAPPARGHSD17B10GAAKDM4E | |
| SCHEMBL2317973 | 0.83 | LMNA (0.66) | PPARAPPARGHSD17B10GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-115916966-A | STRAD binding agents and uses thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-11261190-B2 | Dihydropyrimidine compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-03-01 | — | — | US | disclosed |
| EP-3917527-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113645971-A | Compound and use thereof | 福宏治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-109678859-B | Dihydropyrimidine compound and application thereof in medicine | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200283445-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200283445-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2013003586-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
| EP-0758243-B1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-0758243-A4 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORP (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0758243-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995029682-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿ | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
| US-5444050-A | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-08-22 | — | — | US | disclosed |
| US-5439932-A | Anticholesterol agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0448078-A2 | Substituted amine derivatives having anti-hyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-3985791-A | 16-Phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives | SYNTEX (U.S.A.) INC. (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283445-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | TPMT, DPYD, SLC10A1 | PPARA 577/4885PPARG 829/4885HSD17B10 521/4885 |
| US-11261190-B2 | Dihydropyrimidine compounds and uses thereof in medicine | DPYD, TPMT, SLC10A1 | PPARA 439/4885PPARG 825/4885HSD17B10 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.